Patents by Inventor David James Edmonds

David James Edmonds has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • GLP-1 Receptor Agonists and Uses Thereof
    Publication number: 20190382388
    Abstract: Provided herein are 6-carboxylic acids of benzimidazoles and 4-aza-, 5-aza-, and 7-aza-benzimidazoles as GLP-1R agonists, processes to make said compounds, and methods comprising administering said compounds to a mammal in need thereof.
    Type: Application
    Filed: August 8, 2019
    Publication date: December 19, 2019
    Applicant: Pfizer Inc.
    Inventors: Gary Erik Aspnes, Scott W. Bagley, John M. Curto, David James Edmonds, Mark E. Flanagan, Kentaro Futatsugi, David A. Griffith, Kim Huard, Yajing Lian, Chris Limberakis, Allyn T. Londregan, Alan M. Mathiowetz, David W. Piotrowski, Roger B. Ruggeri
  • Antagonists of prostaglandin EP3 receptor
    Patent number: 9738626
    Abstract: Provided herein are antagonists of prostaglandin EP3 receptor, processes to make said antagonists, and methods comprising administering said antagonists to a mammal in need thereof.
    Type: Grant
    Filed: December 16, 2015
    Date of Patent: August 22, 2017
    Assignee: Pfizer Inc.
    Inventors: Kevin Bahnck, Daniel Canterbury, David James Edmonds, Kentaro Futatsugi, Esther Cheng Yin Lee, Elnaz Menhaji-Klotz, Jana Polivkova, Robert Vernon Stanton
  • Indole and indazole compounds that activate AMPK
    Patent number: 9394285
    Abstract: The present invention relates to indole and indazole compounds of Formula (I) that activate 5? adenosine monophosphate-activated protein kinase (AMPK). The invention also encompasses pharmaceutical compositions containing these compounds and methods for treating or preventing diseases, conditions, or disorders ameliorated by activation of AMPK.
    Type: Grant
    Filed: September 24, 2013
    Date of Patent: July 19, 2016
    Assignee: Pfizer Inc.
    Inventors: Samit Kumar Bhattacharya, Kimberly O'Keefe Cameron, Matthew Scott Dowling, David Christopher Ebner, David James Edmonds, Dilinie Prasadhini Fernando, Kevin James Filipski, Daniel Wei-Shung Kung, Esther Cheng Yin Lee, Aaron Christopher Smith, Meihua Mike Tu
  • ANTAGONISTS OF PROSTAGLANDIN EP3 RECEPTOR
    Publication number: 20160176851
    Abstract: Provided herein are antagonists of prostaglandin EP3 receptor, processes to make said antagonists, and methods comprising administering said antagonists to a mammal in need thereof.
    Type: Application
    Filed: December 16, 2015
    Publication date: June 23, 2016
    Applicant: Pfizer Inc.
    Inventors: Kevin Bahnck, Daniel Canterbury, David James Edmonds, Kentaro Futatsugi, Esther Cheng Yin Lee, Elnaz Menhaji-Klotz, Jana Polivkova, Robert Vernon Stanton
  • Antagonists of prostaglandin EP3 receptor
    Patent number: 9278953
    Abstract: Provided herein are antagonists of prostaglandin EP3 receptor, processes to make said antagonists, and methods comprising administering said antagonists to a mammal in need thereof.
    Type: Grant
    Filed: October 6, 2014
    Date of Patent: March 8, 2016
    Assignee: Pfizer Inc.
    Inventors: Kevin Barry Bahnck, David James Edmonds, Kentaro Futatsugi, Esther Cheng Yin Lee, Alan Martin Mathiowetz, Elnaz Menhaji-Klotz, Robert Vernon Stanton
  • Indole and Indazole Compounds that Activate AMPK
    Publication number: 20160016940
    Abstract: The present invention relates to indole and indazole compounds of Formula (I) that activate 5? adenosine monophosphate-activated protein kinase (AMPK). The invention also encompasses pharmaceutical compositions containing these compounds and methods for treating or preventing diseases, conditions, or disorders ameliorated by activation of AMPK.
    Type: Application
    Filed: September 24, 2013
    Publication date: January 21, 2016
    Applicant: Pfizer, Inc.
    Inventors: Samit Kumar Bhattacharya, Kimberly O'Keefe Cameron, Matthew Scott Dowling, David Christopher Ebner, David James Edmonds, Dilinie Prasadhini Fernando, Kevin James Filipski, Daniel Wei-Shung Kung, Esther Cheng Yin Lee, Aaron Christopher Smith, Meihua Mike Tu
  • SUBSTITUTED ACETYL-COA CARBOXYLASE INHIBITORS
    Publication number: 20150336958
    Abstract: The invention provides a compound of Formula (I) or a pharmaceutically acceptable salt thereof; wherein G is R1, R2 and R3 areas described herein; pharmaceutical compositions thereof; and the use thereof in treating diseases, conditions or disorders modulated by the inhibition of an acetyl-CoA carboxylase enzyme(s) in an animal.
    Type: Application
    Filed: August 7, 2015
    Publication date: November 26, 2015
    Applicant: PFIZER INC.
    Inventors: Robert Lee Dow, David James Edmonds, David Andrew Griffith, James Alfred Southers, JR.
  • SUBSTITUTED ACETYL-COA CARBOXYLASE INHIBITORS
    Publication number: 20150112068
    Abstract: The invention provides a compound of Formula (I) or a pharmaceutically acceptable salt thereof; wherein G is R1, R2 and R3 areas described herein; pharmaceutical compositions thereof; and the use thereof in treating diseases, conditions or disorders modulated by the inhibition of an acetyl-CoA carboxylase enzyme(s) in an animal.
    Type: Application
    Filed: January 9, 2015
    Publication date: April 23, 2015
    Applicant: PFIZER INC.
    Inventors: Robert Lee Dow, David James Edmonds, David Andrew Griffith, James Alfred Southers, JR.
  • ANTAGONISTS OF PROSTAGLANDIN EP3 RECEPTOR
    Publication number: 20150099782
    Abstract: Provided herein are antagonists of prostaglandin EP3 receptor, processes to make said antagonists, and methods comprising administering said antagonists to a mammal in need thereof.
    Type: Application
    Filed: October 6, 2014
    Publication date: April 9, 2015
    Applicant: PFIZER INC.
    Inventors: Kevin Barry Bahnck, David James Edmonds, Kentaro Futatsugi, Esther Cheng Yin Lee, Alan Martin Mathiowetz, Elnaz Menhaji-Klotz, Robert Vernon Stanton
  • SUBSTITUTED ACETYL-COA CARBOXYLASE INHIBITORS
    Publication number: 20140323730
    Abstract: The invention provides a compound of Formula (I) or a pharmaceutically acceptable salt thereof; wherein G is R1, R2 and R3 are as described herein; pharmaceutical compositions thereof; and the use thereof in treating diseases, conditions or disorders modulated by the inhibition of an acetyl-CoA carboxylase enzyme(s) in an animal.
    Type: Application
    Filed: July 8, 2014
    Publication date: October 30, 2014
    Inventors: Robert Lee Dow, David James Edmonds, David Andrew Griffith, James Alfred Southers, JR.
  • Substituted acetyl-coa carboxylase inhibitors
    Patent number: 8802688
    Abstract: The invention provides a compound of Formula (I) or a pharmaceutically acceptable salt thereof; wherein G is R1, R2 and R3 are as described herein; pharmaceutical compositions thereof; and the use thereof in treating diseases, conditions or disorders modulated by the inhibition of an acetyl-CoA carboxylase enzyme(s) in an animal.
    Type: Grant
    Filed: April 21, 2012
    Date of Patent: August 12, 2014
    Assignee: Pfizer Inc.
    Inventors: Robert Lee Dow, David James Edmonds, David Andrew Griffith, James Alfred Southers, Jr.
  • SUBSTITUTED ACETYL-COA CARBOXYLASE INHIBITORS
    Publication number: 20120270893
    Abstract: The invention provides a compound of Formula (I) or a pharmaceutically acceptable salt thereof; wherein G is R1, R2 and R3 are as described herein; pharmaceutical compositions thereof; and the use thereof in treating diseases, conditions or disorders modulated by the inhibition of an acetyl-CoA carboxylase enzyme(s) in an animal.
    Type: Application
    Filed: April 21, 2012
    Publication date: October 25, 2012
    Applicant: PFIZER INC.
    Inventors: Robert Lee Dow, David James Edmonds, David Andrew Griffith, James Alfred Southers, JR.